Skip to content

Dogwood Therapeutics DWTX Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
Bioventus logo
BioventusBVS
Avanos Medical logo
Avanos MedicalAVNS
LON
LeonaBio, Inc. Common StockLONA
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX

Other financials

Income statement

See full
Operating income-$5.1M-14.6%
Net income-$5.0M+54.4%
EPS (diluted)-$0.15+98.2%

Balance sheet

See full
Cash & equivalents$13.2M-24.6%
Total debt$144.9K-24.2%
Total equity$80.6M+1,038%
Total assets$95.2M-1.8%

Cash flow

See full
Operating cash flow-$4.6M+2.0%

Valuation

See full
Market cap$54.14M-57.6%
Enterprise value$41.06M-64.7%

Returns & leverage

See full
Return on equity-64.6%-29.8pp
Debt / equity0.0×
Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dogwood Therapeutics's accrued liabilities, current?
Dogwood Therapeutics (DWTX) reported accrued liabilities, current of $2.35M in Q1 2026.
How has Dogwood Therapeutics's accrued liabilities, current changed year-over-year?
Dogwood Therapeutics's accrued liabilities, current increased by 70.8% year-over-year, from $1.38M to $2.35M.
What is the long-term trend for Dogwood Therapeutics's accrued liabilities, current?
Over 5 years (2020 to 2025), Dogwood Therapeutics's accrued liabilities, current has grown at a 23.4% compound annual growth rate (CAGR), from $784.1K to $2.24M.